The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.

The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments.

The growth of the injectable drug delivery technologies market is driven by factors such as innovations in injectable drug delivery devices, rising prevalence of diabetes in the U.S. and Canada, improving patient compliance and rise in partnerships, collaborations and acquisitions among prominent players in this market. However, factors such as product recalls, regulatory hurdles for approval of new device sand formulations and needle-stick injuries and infections, are restraining the growth of the market.

Scope of the Report

This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Furthermore, due to wide range of applications of injectable drug delivery technologies in varied therapeutic areas, the market is segmented into five categories, namely; auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, Wilson’s Disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Each market is comprehensively analyzed at a granular level by country (United States and Canada) to provide in-depth information on the North American scenario.

Injectable Drug Delivery Technologies Market, By Segment

Injectable Drug Delivery Devices Technologies
Injectable Drug Delivery Formulations Technologies

Injectable Drug Delivery Devices Technologies Market, By Product

Conventional Injection Devices
By Materials
Glass
Plastics
By Product
Fillable Syringes
Prefilled Syringes
By Usability
Reusable
Disposable
Self-Injection Devices
Needle Free Injectors
By Product
Fillable Syringes
Prefilled Syringes
By Technology
Jet-based Needle Free Injectors
Spring-based Needle Free Injectors
Laser Powered Needle Free Injectors
Others
By Usability
Reusable
Disposable
Auto Injectors
By Product
Fillable Syringes
Prefilled Syringes
By Technology
Manual Injection Auto Injectors
Automated Injection Auto Injectors
By Design
Standardized Auto Injectors
Customized Auto Injectors
By Usability
Reusable
Disposable
Pen Injectors
By Product
Single Chambered Pen Injectors
Dual Chambered Pen Injectors
By design
Standardized pen injectors
Customized pen injectors
By usability
Reusable
Disposable
Others (blunt needle, micro needle, and nano needle injections)

Injectable Drug Delivery Formulations Technologies, By Product

Conventional Drug Delivery Formulation
Solution
Reconstituted / Lyophilized Formulation
Novel Drug Delivery Formulation
Liposomal Systems
Microspheres
Nanoparticles
Polymeric Micelles
Others (dendrimers, nanosponge, and nanoemulsions)

Injectable Drug Delivery Technologies Market, B y Therapeutic Applications

Auto Immune Diseases
Multiple Sclerosis
Rheumatoid Arthritis
Crohn's Diseases
Psoriasis
Others
Hormonal Disorders
Diabetes
Antithrombotic/Thrombolytic Therapy
Reproductive Health Diseases
Anemia
Osteoporosis
Others
Orphan Diseases
Oncology
Others
Pain Management
Allergies
Hepatitis C
Aesthetic Treatment

Table Of Contents

TABLE OF CONTENTS

1 INTRODUCTION 22

1.1 KEY TAKE-AWAYS 22
1.2 REPORT DESCRIPTION 22
1.3 MARKETS COVERED 24
1.4 STAKEHOLDERS 27
1.5 RESEARCH METHODOLOGY 27
1.5.1 MARKET SIZE 27
1.5.2 MARKET SHARE 28
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 28
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 28
1.5.5 ASSUMPTIONS 29

2 EXECUTIVE SUMMARY 30

3 MARKET OVERVIEW 35

3.1 INTRODUCTION 36
3.2 MARKET SEGMENTATION 40
3.3 MARKET DYNAMICS 42
3.4 DRIVERS 43
3.4.1 INNOVATIONS IN INJECTABLE DRUG DELIVERY DEVICES 43
3.4.2 SURGE OF BIOLOGICS 44
3.4.3 RISING PREVALENCE OF DIABETES IN THE U.S.
AND CANADA 44
3.4.4 IMPROVEMENT IN PATIENT COMPLIANCE 45
3.4.5 INCESSANT RISE IN PARTNERSHIPS, COLLABORATIONS AND ACQUISITIONS 46
3.5 RESTRAINTS 47
3.5.1 PRODUCT RECALLS 47
3.5.2 STRINGENT REGULATORY SYSTEMS 47
3.5.3 NEEDLE-STICK INJURIES AND INFECTIONS 48
3.6 OPPORTUNITIES 49
3.6.1 DEVELOPMENT OF BIOSIMILARS 49
3.6.2 ADVANCEMENTS IN NANOTECHNOLOGY
AND OTHERS 50
3.7 CHALLENGES 51
3.7.1 SUSTAINABILITY OF PLAYERS IN HIGHLY COMPETITIVE MARKET 51
3.8 MARKET SHARE ANALYSIS, BY MAJOR PLAYERS 52
3.8.1 INJECTABLE DRUG DELIVERY DEVICES 52

4 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET 56

4.1 INTRODUCTION 57
4.2 MARKET SEGMENTATION 60
4.3 MANUFACTURERS CRITERIA FOR SELECTION OF AN INJECTABLE DEVICE 61
4.4 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 63
4.4.1 BY USABILITY 65
4.4.1.1 Disposable 65
4.4.1.2 Reusable 66
4.4.2 BY MATERIAL 68
4.4.2.1 Glass 68
4.4.2.2 Plastic 70
4.4.3 BY PRODUCT 71
4.4.3.1 Prefilled 72
4.4.3.2 Fillable 74
4.5 SELF-INJECTION DEVICES 75
4.5.1 MARKET SEGMENTATION 79
4.5.2 SELECTION CRITERIA FOR SELF-INJECTION DEVICE 79
4.5.3 PEN INJECTORS 81
4.5.3.1 By Product 83
4.5.3.1.1 Single chamber pen injectors 84
4.5.3.1.2 Dual chamber pen injectors 86
4.5.3.2 By Usability 87
4.5.3.2.1 Disposable pen injectors 88
4.5.3.2.2 Reusable pen injectors 89
4.5.3.3 By Design 90
4.5.3.3.1 Standard pen injectors 91
4.5.3.3.2 Customized pen injectors 92
4.5.4 NEEDLE-FREE INJECTORS 93
4.5.4.1 By Product 95
4.5.4.1.1 Prefilled needle free injectors 95
4.5.4.1.2 Fillable needle free injectors 96
4.5.4.2 By Technology 98
4.5.4.2.1 Jet-based needle-free injectors 99
4.5.4.2.2 Spring-based needle-Free injectors 100
4.5.4.2.3 Laser-based needle free injectors 101
4.5.4.2.4 Vibration-based needle free injectors 102
4.5.4.3 By Usability 104
4.5.4.3.1 Disposable 104
4.5.4.3.2 Reusable 106
4.5.5 AUTO INJECTORS 107
4.5.5.1 By Product 109
4.5.5.1.1 Prefilled auto injectors 109
4.5.5.1.2 Fillable auto injectors 111
4.5.5.2 By Technology 112
4.5.5.2.1 Automated auto injectors 112
4.5.5.2.2 Manual auto injectors 113
4.5.5.3 By Design 115
4.5.5.3.1 Standardized auto injectors 115
4.5.5.3.2 Customized auto injectors 117
4.5.5.4 By Usability 118
4.5.5.4.1 Disposable auto injectors 118
4.5.5.4.2 Reusable auto injectors 120
4.6 OTHERS 121

5 INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET 123

5.1 INTRODUCTION 124
5.2 CONVENTIONAL DRUG DELIVERY 126
5.2.1 INJECTABLE SOLUTIONS 129
5.2.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS 131
5.3 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES 133
5.3.1 MARKET SEGMENTATION 135
5.3.2 LIPOSOMAL SYSTEMS 136
5.3.3 MICROSPHERES 138
5.3.4 NANOPARTICLES 140
5.3.5 POLYMERIC MICELLES 141
5.3.6 OTHERS 143

6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS 145

6.1 INTRODUCTION 146
6.2 AUTO-IMMUNE DISEASES 150
6.2.1 MULTIPLE SCLEROSIS 152
6.2.2 RHEUMATOID ARTHRITIS 154
6.2.3 CROHN'S DISEASE 155
6.2.4 PSORIASIS 156
6.2.5 OTHERS 158
6.3 HORMONAL DISORDERS 159
6.3.1 DIABETES 161
6.3.2 ANEMIA 163
6.3.3 REPRODUCTIVE HEALTH DISEASES 164
6.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 166
6.3.5 OSTEOPOROSIS 167
6.3.6 GROWTH HORMONE DEFICIENCY 169
6.4 ORPHAN/RARE DISEASES 171
6.5 ONCOLOGY 173
6.6 OTHERS 175
6.6.1 PAIN MANAGEMENT 176
6.6.2 HEPATITIS C 178
6.6.3 ALLERGIES 179
6.6.4 AESTHETIC TREATMENT 181

7 GEOGRAPHIC ANALYSIS 183

7.1 INTRODUCTION 184
7.1.1 U.S. 186
7.1.1.1 Product innovation stimulating the growth of injectable drug delivery devices in U.S. 187
7.1.1.2 Incessant rise in number of diseases requiring injectable drug delivery-based treatment in U.S. 190
7.1.2 CANADA 192
7.1.2.1 Rise in number of approvals of injectable drug delivery devices 193
7.1.2.2 Canadian market impacted due to shortage of injectable drugs 195
7.1.2.3 Insurance coverage favoring the growth of Canadian injectable drug delivery technology market 197

8 COMPETITIVE LANDSCAPE 198

8.1 INTRODUCTION 198
8.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS and
JOINT VENTURES 202
8.3 NEW PRODUCT LAUNCH 207
8.4 EXPANSION 211
8.5 MERGERS and ACQUISITIONS 214
8.6 OTHER DEVELOPMENTS 216
8.7 APPROVALS 218

9 COMPANY PROFILES 220

9.1 ANTARES PHARMA, INC. 220
9.2 BAXTER INTERNATIONAL, INC. 227
9.3 BECTON, DICKINSON AND COMPANY 233
9.4 ELI LILLY AND COMPANY 240
9.5 HOSPIRA, INC. 246
9.6 NOVO NORDISK A/S 254
9.7 SANOFI 261
9.8 UNILIFE CORPORATION 266
9.9 WEST PHARMACEUTICAL SERVICES, INC. 271
9.10 ZOGENIX, INC. 276



LIST OF TABLES

TABLE 1 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION) 32
TABLE 2 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION) 37
TABLE 3 NORTH AMERICA: INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 39
TABLE 4 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY PRODUCT, 2010 - 2017 ($MILLION) 58
TABLE 5 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 59
TABLE 6 NORTH AMERICA: CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 63
TABLE 7 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,
BY USABILITY, 2010 - 2017 ($MILLION) 65
TABLE 8 DISPOSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 66
TABLE 9 REUSABLE CONVENTIONAL DEVICES MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 67
TABLE 10 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,
BY MATERIAL, 2010 - 2017 ($MILLION) 68
TABLE 11 CONVENTIONAL INJECTION DEVICES (GLASS) MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 69
TABLE 12 CONVENTIONAL INJECTION DEVICES (PLASTIC) MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 70
TABLE 13 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET,
BY PRODUCT, 2010 - 2017 ($MILLION) 72
TABLE 14 NORTH AMERICA: PREFILLED CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 73
TABLE 15 NORTH AMERICA: FILLABLE CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 74
TABLE 16 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 - 2017 ($MILLION) 76
TABLE 17 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 78
TABLE 18 NORTH AMERICA: PEN INJECTOR MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 83
TABLE 19 NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT,
2010 - 2017 ($MILLION) 84
TABLE 20 NORTH AMERICA: SINGLE CHAMBER PEN INJECTOR MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 85
TABLE 21 NORTH AMERICA: DUAL CHAMBER PEN INJECTOR MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 86
TABLE 22 NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY,
2010 - 2017 ($MILLION) 87
TABLE 23 NORTH AMERICA: DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 88
TABLE 24 NORTH AMERICA: REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 89
TABLE 25 NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN,
2010 - 2017 ($MILLION) 90
TABLE 26 NORTH AMERICA: STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 91
TABLE 27 NORTH AMERICA: CUSTOMIZED PEN INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 92
TABLE 28 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 94
TABLE 29 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY PRODUCT, 2010 - 2017 ($MILLION) 95
TABLE 30 NORTH AMERICA: PREFILLED NEEDLE FREE INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 96
TABLE 31 NORTH AMERICA: FILLABLE NEEDLE FREE INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 97
TABLE 32 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION) 98
TABLE 33 NORTH AMERICA: JET-BASED NEEDLE FREE INJECTOR MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 99
TABLE 34 NORTH AMERICA: SPRING-BASED NEEDLE FREE INJECTOR MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 100
TABLE 35 NORTH AMERICA: LASER-POWERED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 101
TABLE 36 NORTH AMERICA: VIBRATION-BASED NEEDLE FREE INJECTOR MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 103
TABLE 37 NORTH AMERICA: NEEDLE FREE INJECTORS MARKET, BY USABILITY, 2010 - 2017 ($MILLION) 104
TABLE 38 NORTH AMERICA: DISPOSABLE NEEDLE FREE INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 105
TABLE 39 NORTH AMERICA: REUSABLE NEEDLE FREE INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 106
TABLE 40 NORTH AMERICA: AUTO INJECTORS PRODUCTS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 108
TABLE 41 NORTH AMERICA: AUTO INJECTORS MARKET, BY PRODUCT,
2010 - 2017 ($MILLION) 109
TABLE 42 NORTH AMERICA: PREFILLED AUTO INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 110
TABLE 43 NORTH AMERICA: FILLABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 111
TABLE 44 NORTH AMERICA: AUTO INJECTORS MARKET, BY TECHNOLOGY,
2010 - 2017 ($MILLION) 112
TABLE 45 NORTH AMERICA: AUTOMATED AUTO INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 113
TABLE 46 NORTH AMERICA: MANUAL AUTO INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 114
TABLE 47 NORTH AMERICA: AUTO INJECTORS MARKET, BY DESIGN,
2010 - 2017 ($MILLION) 115
TABLE 48 NORTH AMERICA: STANDARDIZED AUTO INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 116
TABLE 49 NORTH AMERICA: CUSTOMIZED AUTO INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 117
TABLE 50 NORTH AMERICA: AUTO INJECTORS MARKET, BY USABILITY,
2010 - 2017 ($MILLION) 118
TABLE 51 NORTH AMERICA: DISPOSABLE AUTO INJECTORS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 119
TABLE 52 NORTH AMERICA: REUSABLE AUTO INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 120
TABLE 53 NORTH AMERICA: OTHERS INJECTORS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 121
TABLE 54 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION) 124
TABLE 55 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 125
TABLE 56 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 - 2017 ($MILLION) 127
TABLE 57 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 129
TABLE 58 NORTH AMERICA: INJECTABLE SOLUTIONS CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 130
TABLE 59 NORTH AMERICA: RECONSTITUTED/LYOPHILIZED CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 131
TABLE 60 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 - 2017 ($MILLION) 133
TABLE 61 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 135
TABLE 62 NORTH AMERICA: LIPOSOME DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 137
TABLE 63 NORTH AMERICA: MICROSPHERES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 139
TABLE 64 NORTH AMERICA: NANOPARTICLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 140
TABLE 65 NORTH AMERICA: POLYMERIC MICELLES DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 142
TABLE 66 NORTH AMERICA: OTHERS NOVEL DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 143
TABLE 67 NORTH AMERICAN INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 - 2017 ($MILLION) 146
TABLE 68 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET,
BY INDICATION, 2010 - 2017 ($MILLION) 151
TABLE 69 NORTH AMERICA: AUTO IMMUNE THERAPEUTICS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 152
TABLE 70 NORTH AMERICA: MULTIPLE SCLEROSIS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 153
TABLE 71 NORTH AMERICA: RHEUMATOID ARTHRITIS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 154
TABLE 72 NORTH AMERICA: CROHN'S DISEASE MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 156
TABLE 73 PSORIASIS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 157
TABLE 74 NORTH AMERICA: OTHER AUTO IMMUNE DISEASE MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 158
TABLE 75 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY INDICATION, 2010 - 2017 ($MILLION) 160
TABLE 76 NORTH AMERICA: HORMONAL DISORDERS MARKET, BY COUNTRY, 2010 - 2017($MILLION) 161
TABLE 77 NORTH AMERICA: DIABETES MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 162
TABLE 78 NORTH AMERICA: ANEMIA MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 163
TABLE 79 NORTH AMERICA: REPRODUCTIVE HEALTH DISEASE MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 165
TABLE 80 NORTH AMERICA: ANTITHROMBOTIC THERAPY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 166
TABLE 81 NORTH AMERICA: OSTEOPOROSIS MARKET, BY COUNTRY,
2010 - 2017($MILLION) 168
TABLE 82 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 169
TABLE 83 NORTH AMERICA: ORPHAN/RARE DISEASE MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 171
TABLE 84 NORTH AMERICA: ONCOLOGY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 173
TABLE 85 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY INDICATION, 2010 - 2017 ($MILLION) 175
TABLE 86 NORTH AMERICA: OTHER THERAPEUTIC MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 176
TABLE 87 NORTH AMERICA: PAIN MANAGEMENT MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 177
TABLE 88 NORTH AMERICA: HEPATITIS C MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 178
TABLE 89 NORTH AMERICA: ALLERGIES/ANAPHYLYTIC SHOCK MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 180
TABLE 90 NORTH AMERICA: AESTHETIC TREATMENT MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 181
TABLE 91 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 184
TABLE 92 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION) 186
TABLE 93 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2010 - 2017 ($MILLION) 187
TABLE 94 UNITED STATES: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY PRODUCT, 2010 - 2017($MILLION) 188
TABLE 95 UNITED STATES: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 - 2017 ($MILLION) 190
TABLE 96 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2010 - 2017 ($MILLION) 192
TABLE 97 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,
BY PRODUCT, 2010 - 2017 ($MILLION) 193
TABLE 98 CANADA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 - 2017 ($MILLION) 194
TABLE 99 CANADA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC APPLICATION, 2010 - 2017 ($MILLION) 196
TABLE 100 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS and JOINT VENTURES, 2010 - 2013 202
TABLE 101 NEW PRODUCT LAUNCH, 2010 - 2013 207
TABLE 102 EXPANSION, 2010 - 2012 211
TABLE 103 MERGERS and ACQUISITIONS, 2010 - 2013 214
TABLE 104 OTHERS, 2010 - 2013 216
TABLE 105 APPROVALS, 2010 - 2013 218
TABLE 106 ANTARES PHARMA: TOTAL REVENUES AND RandD EXPENDITURE,
2010 - 2012 ($MILLION) 221
TABLE 107 ANTARES PHARMA: TOTAL REVENUE, BY PRODUCT,
2010 - 2012 ($MILLION) 221
TABLE 108 ANTARES PHARMA: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 222
TABLE 109 BAXTER INTERNATIONAL: TOTAL REVENUE AND RandD EXPENSES,
2010 - 2012 ($MILLION) 228
TABLE 110 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 228
TABLE 111 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE,
2010 - 2012($MILLION) 229
TABLE 112 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 230
TABLE 113 BECTON DICKINSON: TOTAL REVENUE AND RandD EXPENDITURE,
2010 - 2012 ($MILLION) 234
TABLE 114 BECTON DICKINSON: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 234
TABLE 115 BECTON DICKINSON: MEDICAL DIVISION TOTAL REVENUE,
2010 - 2012 ($MILLION) 235
TABLE 116 BECTON DICKINSON: TOTAL REVENUE, BY GEOGRAPHY,
2010- 2012 ($MILLION) 235
TABLE 117 ELI LILLY and CO: TOTAL REVENUE AND RandD EXPENSES,
2010 - 2012 ($BILLION) 241
TABLE 118 ELI LILLY and CO: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($BILLION) 241
TABLE 119 ELI LILLY and CO: TOTAL REVENUE BY GEOGRAPHY,
2010 - 2012 ($BILLION) 242
TABLE 120 HOSPIRA, INC.: TOTAL REVENUE AND RandD EXPENDITURE,
2009 - 2011 ($MILLION) 247
TABLE 121 HOSPIRA, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION) 247
TABLE 122 HOSPIRA, INC.: TOTAL REVENUE, BY SEGMENT,
2009 - 2011($MILLION) 248
TABLE 123 NOVO NORDISK: TOTAL REVENUE AND RandD EXPENSES,
2010 - 2012 ($BILLION) 255
TABLE 124 NOVO NORDISK: TOTAL REVENUE, BY SEGMENT,
2010 - 2012($BILLION) 255
TABLE 125 NOVO NORDISK: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($BILLION) 256
TABLE 126 SANOFI: TOTAL REVENUE and RandD EXPENDITURE,
2009 - 2012 ($BILLION) 262
TABLE 127 SANOFI: TOTAL REVENUE, BY SEGMENT, 2009 - 2012 ($BILLION) 262
TABLE 128 SANOFI: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2012 ($BILLION) 263
TABLE 129 UNILIFE CORPORATION: TOTAL REVENUE AND EXPENDITURE,
2009 - 2011 ($MILLION) 267
TABLE 130 UNILIFE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION) 267
TABLE 131 WEST PHARMA: TOTAL REVENUES AND RandD EXPENSES,
2009 - 2012 ($MILLION) 272
TABLE 132 WEST PHARMA: TOTAL REVENUE, BY SEGMENT,
2009 - 2012 ($MILLION) 272
TABLE 133 WEST PHARMA: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2012 ($MILLION) 273
TABLE 134 ZOGENIX, INC.: TOTAL REVENUE AND RandD EXPENDITURE,
2010 - 2012 ($MILLION) 277



LIST OF FIGURES

FIGURE 1 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET 31
FIGURE 2 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY 33
FIGURE 3 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION 36
FIGURE 4 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES 40
FIGURE 5 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATION 41
FIGURE 6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET DYNAMICS 42
FIGURE 7 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET,
BY KEY PLAYERS, 2012 52
FIGURE 8 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET SEGMENTATION 60
FIGURE 9 FACTORS AFFECTING SELECTION OF AN INJECTABLE DEVICE 61
FIGURE 10 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 and 2017 ($MILLION) 77
FIGURE 11 SELF-INJECTION DEVICES MARKET SEGMENTATION 79
FIGURE 12 FACTORS AFFECTING SELECTION OF SELF-INJECTION DEVICE 80
FIGURE 13 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET SEGMENTATION 126
FIGURE 14 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2012 and 2017 128
FIGURE 15 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET 134
FIGURE 16 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES SEGMENTATION 136
FIGURE 17 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 - 2017 ($MILLION) 148
FIGURE 18 INJECTABLE DRUG DELIVERY THERAPEUTICS MARKET SEGMENTATION 149
FIGURE 19 AUTO-IMMUNE THERAPEUTICS MARKET SEGMENTATION 150
FIGURE 20 HORMONAL DISORDERS MARKET SEGMENTATION 159
FIGURE 21 KEY GROWTH STRATEGIES, 2010 - 2013 198
FIGURE 22 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES STRATEGY, 2010 - 2013 199
FIGURE 23 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,
2010 - 2013 200
FIGURE 24 KEY PLAYERS FOCUSING ON EXPANSION, 2010 - 2013 201

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

RNAi Drug Delivery : Technologies and Gobal Markets

RNAi Drug Delivery : Technologies and Gobal Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious ...

Lyophilization Market by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, & Others), Technology (Tray-style, Manifold, & Rotary) & Geography - Global Trends & Forecast to 2019

Lyophilization Market by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, & Others), Technology (Tray-style, Manifold, & Rotary) & Geography - Global Trends & Forecast to 2019

  • $ 4 650
  • Industry report
  • September 2014
  • by MarketsandMarkets

Lyophilization or freeze-drying has significant applications in the food, pharmaceutical, and biotechnology industry and is used as a standard process to stabilize, store, and increase the shelf-life of ...

Global Transdermal Drug Delivery Market 2014-2018

Global Transdermal Drug Delivery Market 2014-2018

  • $ 2 500
  • Industry report
  • June 2014
  • by Infiniti Research Limited

About Transdermal Drug Delivery Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.